{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:10:50Z","timestamp":1775149850643,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"am","delay-in-days":320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Tropica"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.actatropica.2019.01.009","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T11:00:15Z","timestamp":1547031615000},"page":"204-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Meta-analysis and discussion on challenges to translate Leishmania drug resistance phenotyping into the clinic"],"prefix":"10.1016","volume":"191","author":[{"given":"Denis","family":"Sereno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoubir","family":"Harrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naouel","family":"Eddaikra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.actatropica.2019.01.009_bib0005","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.vetpar.2012.01.034","article-title":"In vitro susceptibility to antimonials and amphotericin B of Leishmania infantum strains isolated from dogs in a region lacking drug selection pressure","volume":"187","author":"A\u00eft-Oudhia","year":"2012","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004349","article-title":"A historical overview of the classification, evolution, and dispersion of Leishmania parasites and sandflies","volume":"10","author":"Akhoundi","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2016.11.012","article-title":"Leishmania infections: molecular targets and diagnosis","volume":"57","author":"Akhoundi","year":"2017","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.actatropica.2019.01.009_bib0025","doi-asserted-by":"crossref","first-page":"e00048","DOI":"10.1128\/CMR.00048-18","article-title":"Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives","volume":"31","author":"Alves","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0030","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/cid\/ciw742","article-title":"Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)","volume":"63","author":"Aronson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0035","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2307\/3281406","article-title":"Leishmania tropica: quantitation of in vitro activity of antileishmanial agents by Giemsa staining, viability, and 3H-formycin B incorporation","volume":"70","author":"Berman","year":"1984","journal-title":"J. Parasitol."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001657","article-title":"Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis","volume":"6","author":"Bhandari","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0045","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.actatropica.2017.07.026","article-title":"Leishmaniasis in the major endemic region of Plurinational State of Bolivia: species identification, phylogeography and drug susceptibility implications","volume":"176","author":"Bilbao-Ramos","year":"2017","journal-title":"Acta Trop."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0050","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1021\/pr201248h","article-title":"Analysis of membrane-enriched and high molecular weight proteins in Leishmania infantum promastigotes and axenic amastigotes","volume":"11","author":"Brotherton","year":"2012","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0051862","article-title":"Cutoff Finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization","volume":"7","author":"Budczies","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.actatropica.2019.01.009_bib0060","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/bmj.2.2637.104","article-title":"Intramuscular and intravenous injections of antimony in trypanosomiasis","volume":"2","author":"Camac","year":"1911","journal-title":"Br. Med. J."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0065","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3201\/eid1804.110841","article-title":"Leishmania resistance to miltefosine associated with genetic marker","volume":"18","author":"Cojean","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1462-5822.2010.01521.x","article-title":"A combined luciferase imaging and reverse transcription polymerase chain reaction assay for the study of Leishmania amastigote burden and correlated mouse tissue transcript fluctuations","volume":"13","author":"De La Llave","year":"2011","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005641","article-title":"Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress","volume":"11","author":"Deep","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0080","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine, a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0085","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.pt.2009.06.006","article-title":"Reporter genes facilitating discovery of drugs targeting protozoan parasites","volume":"25","author":"Dube","year":"2009","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0090","article-title":"Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria","volume":"1","author":"Eddaikra","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.actatropica.2017.12.020","article-title":"Antimonial susceptibility and in vivo behaviour of Leishmania major isolates collected in Algeria before and after treatment","volume":"180","author":"Eddaikra","year":"2018","journal-title":"Acta Trop."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0100","series-title":"Leishmania. In: In Vitro Methods for Parasite Cultivation","first-page":"52","author":"Evans","year":"1987"},{"key":"10.1016\/j.actatropica.2019.01.009_bib0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.micpath.2014.10.012","article-title":"Simultaneous multi-parametric analysis of Leishmania and of its hosting mammal cells: a high content imaging-based method enabling sound drug discovery process","volume":"88","author":"Forestier","year":"2015","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0001-706X(92)90042-V","article-title":"An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1","volume":"51","author":"Gebre-Hiwot","year":"1992","journal-title":"Acta Trop."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0115","series-title":"Manual on Case Management and Surveillance of the Leishmaniases in the WHO European Region","author":"Gradoni","year":"2017"},{"key":"10.1016\/j.actatropica.2019.01.009_bib0120","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1471-4922(00)01811-0","article-title":"In vitro cultivation and characterization of axenic amastigotes of Leishmania","volume":"17","author":"Guptan","year":"2001","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0125","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1371\/journal.pmed.0030162","article-title":"Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites","volume":"3","author":"Hadighi","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0130","first-page":"1","article-title":"Evaluating drug resistance in visceral leishmaniasis: the challenges","volume":"21","author":"Hendrickx","year":"2016","journal-title":"Parasitology"},{"key":"10.1016\/j.actatropica.2019.01.009_bib0135","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.12613","article-title":"Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent","volume":"5","author":"Imamura","year":"2016","journal-title":"eLife."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0140","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1128\/AAC.00866-09","article-title":"In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells","volume":"53","author":"Inoc\u00eancio da Luz","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0145","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ijantimicag.2016.09.018","article-title":"Development of Leishmania donovani stably expressing DsRed for flow cytometry-based drug screening using chalcone thiazolyl-hydrazone as a new antileishmanial target","volume":"48","author":"Jaiswal","year":"2016","journal-title":"Int. J. Antimicrob. Agent."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0150","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.316.7139.1200","article-title":"Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India","volume":"316","author":"Jha","year":"1998","journal-title":"BMJ."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0155","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/03009734.2014.901446","article-title":"Defining antibiotic resistance-towards international harmonization","volume":"119","author":"Kahlmeter","year":"2014","journal-title":"Ups. J. Med. Sci."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0160","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/apm.12624","article-title":"Normalized resistance interpretation, the NRI method: review of NRI disc test applications and guide to calculations","volume":"124","author":"Kronvall","year":"2016","journal-title":"APMIS"},{"key":"10.1016\/j.actatropica.2019.01.009_bib0165","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1128\/AAC.00812-10","article-title":"Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine","volume":"55","author":"Kulshrestha","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0170","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00436-012-3212-3","article-title":"Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani","volume":"112","author":"Kulshrestha","year":"2013","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0175","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/AAC.01233-08","article-title":"In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity","volume":"53","author":"Kumar","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0180","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1086\/595710","article-title":"Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum","volume":"48","author":"Lachaud","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0185","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.pt.2009.07.006","article-title":"Imaging Leishmania development in their host cells","volume":"25","author":"Lang","year":"2009","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0190","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/nar\/gkn1069","article-title":"Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum","volume":"37","author":"Leprohon","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0195","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00436-008-1048-7","article-title":"Comparison of the expression profiles of promastigotes and axenic amastigotes in Leishmania donovani using serial analysis of gene expression","volume":"103","author":"Li","year":"2008","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0200","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1086\/314896","article-title":"Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani","volume":"180","author":"Lira","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0205","series-title":"Drug Resistance in Leishmania Parasites","article-title":"The relevance of susceptibility tests, breakpoints, and markers","author":"Maes","year":"2013"},{"key":"10.1016\/j.actatropica.2019.01.009_bib0210","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.exppara.2013.05.015","article-title":"In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs","volume":"135","author":"Maia","year":"2013","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0215","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/j.1365-2958.2005.04782.x","article-title":"Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania","volume":"57","author":"Marquis","year":"2005","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0220","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1128\/AAC.42.2.352","article-title":"Mechanism of amphotericin B resistance in Leishmania donovani promastigotes","volume":"42","author":"Mbongo","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0225","doi-asserted-by":"crossref","first-page":"e1323","DOI":"10.1371\/journal.pntd.0001323","article-title":"Luciferase expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro","volume":"5","author":"Michel","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0230","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/0140-6736(92)92952-C","article-title":"Amphotericin versus pentamidine in antimony-unresponsive kala-azar","volume":"340","author":"Mishra","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.actatropica.2019.01.009_bib0235","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4269\/ajtmh.2007.76.681","article-title":"Characterization of natural antimony resistance in Leishmania donovani isolates","volume":"7","author":"Mittal","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154101","article-title":"Genomic and molecular characterization of miltefosine resistance in Leishmania infantum strains with either natural or acquired resistance through experimental selection of intracellular amastigotes","volume":"11","author":"Mondelaers","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.actatropica.2019.01.009_bib0250","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-9292-5-6","article-title":"Leishmania amastigotes as targets for drug screening","volume":"5","author":"Monte-Alegre","year":"2006","journal-title":"Kinetoplastid Biol. Dis."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0255","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4103\/0255-0857.96703","article-title":"Relapse of kala-azar after use of multiple drugs: a case report and brief review of literature","volume":"30","author":"Pandey","year":"2012","journal-title":"Indian J. Med. Microbiol."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0260","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drup.2006.04.001","article-title":"Mechanisms of experimental resistance of Leishmaniato miltefosine: Implications for clinical use","volume":"9","author":"P\u00e9rez-Victoria","year":"2006","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0265","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1462-5822.2011.01593.x","article-title":"Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation","volume":"13","author":"Pescher","year":"2011","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0270","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/jac\/dkf113","article-title":"In vitro susceptibility of Leishmania infantum strains isolated from Spanish HIV-positive patients to Abelcet and Fungizone","volume":"50","author":"Pi\u00f1ero","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006052","article-title":"Drug resistance and treatment failure in leishmaniasis: A 21st century challenge","volume":"11","author":"Ponte-Sucre","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0280","doi-asserted-by":"crossref","first-page":"750","DOI":"10.4269\/ajtmh.13-0096","article-title":"In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis","volume":"89","author":"Prajapati","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0285","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.actatropica.2011.11.015","article-title":"Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivoscreening of antileishmanial drugs","volume":"122","author":"Pulido","year":"2012","journal-title":"Acta Trop."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0290","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1128\/AAC.00030-11","article-title":"Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani","volume":"56","author":"Purkait","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0295","doi-asserted-by":"crossref","first-page":"e00611","DOI":"10.1128\/mBio.00611-13","article-title":"Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain","volume":"4","author":"Rai","year":"2013","journal-title":"MBio"},{"key":"10.1016\/j.actatropica.2019.01.009_bib0300","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/cid\/cit102","article-title":"Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance","volume":"56","author":"Rijal","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0305","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0166-6851(98)00062-0","article-title":"Characterization of developmentally-regulated activities in axenic amastigotes of Leishmania donovani","volume":"95","author":"Saar","year":"1998","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0310","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1128\/CMR.15.3.374-389.2002","article-title":"Cultivation of clinically significant hemoflagellates","volume":"15","author":"Schuster","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0315","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/jac\/dkp500","article-title":"In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent","volume":"65","author":"Seifert","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0320","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.41.5.972","article-title":"Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents","volume":"41","author":"Sereno","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0325","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.parint.2006.09.001","article-title":"Advances and perspectives in Leishmania cell based drug-screening procedures","volume":"56","author":"Sereno","year":"2007","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0330","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ijpddr.2012.07.003","article-title":"Antimony resistance and environment: Elusive links to explore during Leishmania life cycle","volume":"2","author":"Sereno","year":"2012","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0335","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/505079","article-title":"Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis","volume":"194","author":"Singh","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0340","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/jac\/dkp206","article-title":"Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening","volume":"64","author":"Singh","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0345","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13071-017-1969-z","article-title":"Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India","volume":"10","author":"Srivastava","year":"2017","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.actatropica.2019.01.009_bib0350","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-3156.2001.00778.x","article-title":"Drug resistance in Indian visceral leishmaniasis","volume":"6","author":"Sundar","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.actatropica.2019.01.009_bib0355","first-page":"1","article-title":"Chemotherapy of leishmaniasis: present challenges","volume":"20","author":"Uliana","year":"2017","journal-title":"Parasitology"},{"key":"10.1016\/j.actatropica.2019.01.009_bib0360","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.exppara.2013.01.022","article-title":"Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model","volume":"134","author":"Utaile","year":"2013","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0365","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1128\/AAC.00548-09","article-title":"In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences","volume":"53","author":"Vermeersch","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.actatropica.2019.01.009_bib0370","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1086\/507710","article-title":"American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?","volume":"194","author":"Yardley","year":"2006","journal-title":"J. Infect. Dis."}],"container-title":["Acta Tropica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001706X18315432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001706X18315432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:12:20Z","timestamp":1757549540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001706X18315432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":74,"alternative-id":["S0001706X18315432"],"URL":"https:\/\/doi.org\/10.1016\/j.actatropica.2019.01.009","relation":{},"ISSN":["0001-706X"],"issn-type":[{"value":"0001-706X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-analysis and discussion on challenges to translate Leishmania drug resistance phenotyping into the clinic","name":"articletitle","label":"Article Title"},{"value":"Acta Tropica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actatropica.2019.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}